Provide a stabilizing force.
When they need it most.
Has your patient had a worsening heart failure (HF) event recently? It's time to rethink their treatment.
Patients' hearts are never the same again after each worsening HF event.
Every minute, on average 30 patients experience a worsening HF event.
Following a worsening HF event, patients are at an even higher risk of CV death and re-hospitalization
1 in 2 patients will be hospitalized again for a HF event within 30 days of their worsening event.
Patients experience a devastating cycle of escalating symptoms and frequent hospitalizations, which severely affects their lives as well as the lives of their loved ones.
Despite existing therapies, millions of patients experience worsening HF events that disrupt and cut their lives short.
This is where VERQUVO can help.
Introducing a new therapeutic approach for patients who have experienced a worsening chronic HF event.
Verquvo is the only treatment approved for worsening heart failure to target the deficient NO-sGC-cGMP pathway
VERQUVO has been proven to lower the combined risk of CV death and HF hospitalizations following a worsening chronic HF event in adults with heart failure with reduced ejection fraction (HFrEF).
Indication
Vericiguat is indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or need for outpatient Intravenous (IV) diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%.